Brevan Howard Capital Management LP Avidity Biosciences, Inc. Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 32,712 shares of RNA stock, worth $969,910. This represents 0.01% of its overall portfolio holdings.
Number of Shares
32,712
Previous 5,728
471.09%
Holding current value
$969,910
Previous $263,000
261.6%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$327 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$280 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$256 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$240 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$235 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.55B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...